Accordingly, inhibition of ERAP1 was shown to generate strong innate and adaptive anti-tumor immune responses resulting in tumor regression in two distinct tumor mouse models, thus providing evidences that modulation of ERAP1 activity may represent a promising tool for cancer immunotherapy27,36. The gene discussed is ERAP1; the disease is neoplasm.